Baker McKenzie advised EQT on the transaction while Goodwin represented ELEVATE. EQT executed the sale of its interest in ELEVATE, a leading provider of ESG and supply...
LRQA’s Acquisition of Interest in ELEVATE
Acadia Pharmaceuticals’ Collaboration Agreement with Stoke Therapeutics
Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc....
Eluminex Biosciences’ Acquisition of Zuretinol Acetate Assets from Retinagenix
Goodwin Procter advised Eluminex Biosciences on the deal. Eluminex Biosciences (Suzhou) Limited (Eluminex) announced its acquisition of certain assets and the related global development and commercialization rights...
Arrakis Therapeutics’ Collaboration Agreement with Amgen
Goodwin Procter advised Arrakis Therapeutics on the deal. Arrakis Therapeutics announced its research collaboration agreement with Amgen (NASDAQ:AMGN), focused on the discovery and development of RNA degrader...
Amylyx Pharmaceuticals’ $190 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
Generate Biomedicines’ Research Collaboration Agreement with Amgen
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
Global Blood Therapeutics’ $345 Million Notes Offering
Goodwin Procter advised Global Blood Therapeutics on the deal. Global Blood Therapeutics, Inc. (Nasdaq: GBT) announced its offering of 1.875% Convertible Senior Notes due 2028. The...
Aura Biosciences’ $75.6 Million IPO
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
Enfusion’s $367 Million IPO
Goodwin advised Enfusion on the deal, while Davis Polk advised the representatives of the several underwriters. Enfusion, Inc. completed its initial public offering of 21,562,500 shares...
Exscientia’s $510.4 Million IPO
Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital...
Garuda Therapeutics’ Launch and $72 Million Series A Financing
Goodwin Procter advised Garuda Therapeutics on the deal. Garuda Therapeutics announced its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed,...
AbCellera’s Acquisition of TetraGenetics
Goodwin Procter advised AbCellera on the deal. AbCellera (Nasdaq: ABCL) announced its acquisition of TetraGenetics. AbCellera is a technology company with a centralized operating system for next-generation...